Altimmune, Inc. (ALT)
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
$2.14+1.90%
Close 2026-10-29 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
Research Workspace
Put ALT beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Manage and reduce operating losses: Comparison needs review.
View ThesisRevenue growth is accelerating — up about 105% over the past year.
View GrowthMiddle-of-the-pack management execution.
View ManagementExpectations look high — the market is pricing in about 200% growth a year, above the roughly 92% analysts expect, leaving little room for error.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 67% in its worst 12-month stretch.
View RiskALT’s case rests on reducing operating losses, but revenue growth cannot be assessed here. Its latest quarter beat earnings expectations, though ALT remained unprofitable. No clean valuation multiple is available, and the market prices in more growth than forecast. Elevated valuation leaves room for the premium to compress. The loss-reduction comparison needs review, so no confirmed break is established. Peer multiples imply a price about 200% below where it trades. The thesis is on watch, and this read is provisional.
Trailing returns as of 2026-10-29. ALT is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 10 analysts currently covering ALT (as of Oct 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare ALT with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| ALT Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 1 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put ALT next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Board turnover and new directors may affect oversight, but the headline gives no evidence of a thesis change.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Advances: Advance pemvidutide clinical trials in MASH, AUD, and ALD
Pemvidutide push aligns with advancing clinical trials objective.
Advances: Advance pemvidutide clinical trials in MASH, AUD, and ALD
Concurrent progress across three liver trials supports execution of the pemvidutide clinical strategy.
Advances: Advance pemvidutide clinical trials in MASH, AUD, and ALD
Earnings-call highlights indicate continued advancement of MASH and AUD programs.
Advances: Advance pemvidutide clinical trials in MASH, AUD, and ALD
Phase 3 MASH planning and upcoming AUD data mark concrete progress in key programs.
Advances: Advance pemvidutide clinical trials
Reported clinical momentum ahead of Phase 3 supports pemvidutide development, though no new results are specified.
Advances: Advance pemvidutide clinical trials
Positive trial data supports pemvidutide's clinical path.
Threatens: Strengthen financial position through capital raises
Dilution concerns could weaken per-share value despite supporting the financing objective.